Abstract Search

ea0089t9 | Trials In Progress | NANETS2022

PReCedeNT Trial: Phase III Randomised Controlled Trial of PRRT with Lutetium – 177 DOTATATE Plus Chemotherapy vs PRRT Alone in FDG-avid, Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors

D Puranik Ameya , Rangarajan Venkatesh , Ramaswamy Anant , Ostwal Vikas , V Shrikhande Shailesh , Bhandare Manish , Chaudhari Vikram , M Bal Munita , Agrawal Archi , C Purandare Nilendu , Shah Sneha

Background: Well-differentiated GEP NETs show positive uptake on Ga-68-DOTATOC PET/CT, a somatostatin-receptor (SSTR)-specific imaging tracer. 18F-FDG PET/CT is preferred for aggressive, high-grade NETs as GLUT (glucose-transporter) receptor expression entails poorer prognosis. Grade 2 NET may demonstrate heterogenous uptake of both tracers; suggestive of tumor heterogeneity. PRRT is widely available at reasonable cost since Lu-177-DOTATATE is manufactured indegenously, and is...

2 shares

Endocrine Abstracts

PReCedeNT Trial: Phase III Randomised Controlled Trial of PRRT with Lutetium – 177 DOTATATE Plus Chemotherapy vs PRRT Alone in FDG-avid, Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors

BiosciAbstracts